PT-141 (Bremelanotide): Mechanisms & Research

What is PT-141?

PT-141 / bremelanotide is a cyclic heptapeptide structurally derived from the broader melanotan II family. Where melanotan II is non-selective and dominated by MC1R-mediated pigmentation effects, bremelanotide was engineered for higher relative activity at MC4R — the central melanocortin receptor implicated in sexual function, energy balance, and inflammation — while retaining MC1R activity that contributes to anti-inflammatory and protective effects in some models.

This selectivity profile is the central distinction between PT-141 and melanotan II: both are α-MSH analogs, but bremelanotide is the optimized clinical candidate with reduced pigmentation potency relative to its central MC4R activity. PT-141 is supplied as a lyophilized powder for research use, typically certified at >=98% purity by HPLC; review the Certificate of Analysis before incorporating into a protocol.

Mechanism of Action

PT-141 acts through the central nervous system rather than the peripheral vasculature, which is the key mechanistic distinction from PDE5 inhibitors and the basis of its registered HSDD indication.

Pharmacokinetics

Bremelanotide is administered subcutaneously in the registered Vyleesi formulation, with a plasma half-life on the order of two hours in published human PK studies. Peak concentrations occur within approximately one hour of SC injection, and the molecule is cleared primarily through hepatic metabolism with proteolytic breakdown of the cyclic peptide structure.

Earlier development programs evaluated intranasal delivery, which produced acute pharmacokinetic exposure suitable for on-demand use but was associated with transient blood pressure increases that contributed to the discontinuation of the intranasal program. The SC route was selected for the registered Vyleesi product on the basis of more controlled exposure and a more acceptable cardiovascular profile. Tissue distribution studies show CNS penetration sufficient for hypothalamic MC4R engagement at clinical doses, consistent with the central mechanism.

Clinical and Research History

Bremelanotide's clinical record includes both completed registration trials and a parallel mechanistic research literature.

Phase II/III HSDD trials (RECONNECT studies) — Two pivotal Phase III randomized, placebo-controlled trials in premenopausal women with HSDD demonstrated statistically significant improvements in desire and reductions in distress scales relative to placebo, supporting the 2019 FDA approval. Safarinejad and colleagues, and the Palatin/AMAG sponsor groups, published the trial program through 2018-2019.

Vyleesi FDA approval (2019) — Bremelanotide was approved by the FDA in June 2019 as Vyleesi for HSDD in premenopausal women, administered as a 1.75 mg SC autoinjector dose used as needed prior to anticipated activity. Earlier erectile-dysfunction development was discontinued.

Military TBI and hemorrhagic shock research — Investigators at the U.S. Army Institute of Surgical Research and academic collaborators have studied bremelanotide and related melanocortin agonists in rodent models of hemorrhagic shock and traumatic brain injury, with reported reductions in inflammatory cytokine release and improvements in survival in standardized models. This line of work draws on the MC1R/MC4R anti-inflammatory mechanism rather than the sexual-function indication.

Mechanistic primary literature — Pfaus and colleagues established the rodent behavioral pharmacology, Molinoff and colleagues at Palatin published medicinal-chemistry and receptor-selectivity work, and Ramos-Vara and others contributed to characterization of melanocortin receptor distribution and function.

Safety Considerations

The bremelanotide safety profile is well characterized from the Vyleesi registration program. The most commonly reported adverse events in the Phase III trials were nausea (the most frequent reason for discontinuation), flushing, injection-site reactions, and headache. Two cardiovascular signals warrant specific note.

First, bremelanotide produces a transient increase in blood pressure and decrease in heart rate in the hours following administration; the labeling carries a contraindication for uncontrolled hypertension and known cardiovascular disease. Second, focal hyperpigmentation of the face, gums, and breasts has been reported with repeated dosing, attributable to MC1R activity; it is more common at higher cumulative exposure and is dose-related. These are factual safety observations from the registered clinical record, not editorial commentary. Researchers should design protocols around the published exposure profile and review storage and handling guidance in our storage reference.

Conclusion

PT-141 / bremelanotide is one of the few peptide research compounds with a registered human indication (Vyleesi for HSDD, FDA 2019), giving it an unusually solid clinical and mechanistic dossier compared with most research-grade peptides. Its central MC4R/MC1R agonism distinguishes it pharmacologically from peripheral vasoactive treatments and motivates ongoing research interest in inflammation, shock, and TBI models. Outside the registered Vyleesi indication, the compound remains a research-use peptide; protocols should be designed around the published PK and safety profile and within the bounds of our research disclaimer.

Frequently Asked Questions